You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of a novel highly effective influenza vaccine
SBC: FLUGEN INC Topic: NIAIDDESCRIPTION provided by applicant Seasonal influenza flu virus an NIAID category C priority pathogen causes widespread infection resulting in at least million cases of severe illness and deaths worldwide Young children and elderly or immunocompromised individuals are typically at greater risk of severe illness or death from influenza Newly emerging strains can result ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
New heterocyclic inhibitors of filoviruses
SBC: MICROBIOTIX, INC. Topic: HDESCRIPTION provided by applicant Ebola and Marburg viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral i ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Nitric Oxide Microfluidic Sensor
SBC: CLINICAL SENSORS, INC. Topic: NIAIDDESCRIPTION provided by applicant This Small Business Innovation Research SBIR Phase I project aims to develop a microfluidic based nitric oxide NO sensor as an early sepsis risk assessment device Sepsis causes significant strain on the U S healthcare system consuming over $ billion annually due to extended hospital stays and significant morbidity and mortality Rapid diagnosis and in ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
New small molecule inhibitors of arenaviruses
SBC: MICROBIOTIX, INC. Topic: RDESCRIPTION provided by applicant Lassa fever virus LASV and Machupo virus MACV are hemorrhagic fever arenaviruses which are classified as Category A Agents Currently there are no licensed LASV or MACV vaccines and LASV MACV therapy is limited to use of the nucleoside analog ribavirin which is only partially effective and associated with significant side effects The impact of arenavirus ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Novel commensal polysaccharide treats multiple sclerosis through Treg modulation
SBC: SYMBIOTIX BIOTHERAPIES, INC. Topic: NIAIDAbstract Multiple sclerosis (MS) is a chronic demyelinating inflammatory disease that is the most common neurological disease of young adults, affecting over 350,000 patients in the US and over 2.5 million patients worldwide. MS is a disease of high unmetmedical need, currently treatable with one of several approved drugs, all of which result in either immune modulation or significant immunosuppre ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
AAV2-ASPA-Based Metabolic Intervention for Alzheimer's Disease
SBC: ASKLEPIOS BIOPHARMACEUTICAL, INC. Topic: NIAAbstract We propose to initiate preclinical development of a gene therapeutic targeted to Alzheimer's Disease. The World Health Organization's and Alzheimer's Disease International's report on Dementia (2012) recognizes that the global burden of AlzheimerDisease is forecast to worsen significantly with prevalence predicted to double every 20 years. Interventions that could prov ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Picture Me Fit: Engaging Youth in Community-Based Prevention
SBC: PREVENTION STRATEGIES, LLC Topic: 600DESCRIPTION provided by applicant Approximately one third of all U S adults and children are obese and at risk for a wide range of related chronic health conditions such as cardiovascular disease hypertension diabetes stroke osteoarthritis sleep apnea and certain types of cancer The Center for Disease Control and Prevention CDC and other expert resources recognize that although indivi ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
New Class of Bright, Sharp, Tunable Near-Infrared Fluorophores for Flow Cyto
SBC: Nirvana Sciences, Inc. Topic: NIAIDDESCRIPTION (provided by applicant): Polychromatic flow cytometry [FC] is one of the most powerful analytical techniques routinely used in immunology. Flow cytometry plays a critical role in several growing clinical applications: leukemia and lymphoma immunophenotyping for diagnosis and sub-categorization (now using 8-10 colors); in CD4/CD8 measurement in HIV-positive patients; and in HLA typing f ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
DNP Polarization Agents for Real-Time Metabolic Imaging and Clinical Diagnosis
SBC: DYNUPOL, INC. Topic: NCIProject Summary / Abstract Although standard MRI techniques provide valuable structural insight, a related technique known as magnetic resonance spectroscopy (MRS) adds powerful real-time metabolic information about the tissues under study. MRS provides early detection of disease, monitoring treatment efficacy, and, in the case of cancer, a dramatic reduction in unnecessary biopsies. However, bro ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
F10: a novel therapeutic to treat refractory or relapsed AML
SBC: SOUTHEAST TECHINVENTURES INC Topic: NCIDESCRIPTION (provided by applicant): Acute myeloid leukemia (AML) affected ~14,600 new patients in 2013 in the US and caused over 10,000 deaths, primarily in older adults. The current chemotherapy regimen, a combination of cytarabine (AraC) and anthracyclines such as daunorubicin (DNR), has resulted in 5-year survival rates of only 30-40% (less than 10% in patients over 60 years old). The principa ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health